利妥昔单抗在急性淋巴细胞白血病中的临床应用

周进; 傅琤琤

利妥昔单抗在急性淋巴细胞白血病中的临床应用

周进,
傅琤琤^,

- 苏州大学附属第一医院血液科(江苏苏州, 215006)

详细信息

通讯作者: 傅琤琤,E-mail:zhenzhenFu@hotmail.com

中图分类号: R733.71

收稿日期: 2012-10-21

Clinical application of rituximab in patients with acute lymphoblastic leukemia

ZHOU Jin,
FU Chengcheng^,

More Information

Corresponding author: FU Chengcheng, E-mail: zhenzhenFu@hotmail.com

Received Date: 21 October 2012

摘要

- 急性淋巴细胞白血病 /
- 利妥昔单抗 /
- CD20
Abstract: Rituximab is a human mouse chimeric monoclonal antibody,which has been gradually applied in B cell acute lymphoblastic leukemia (ALL).Whether CD20 influences the prognosis of precursor B cells ALL for children and adults remains controversial.Rituximab with multidrug therapy which showed in several studies can effectively cure precursor B cells ALL and improve the prognosis of patients with mature B cells.Rituximab combined preparative regimens can effectively play resistant effects of acute graft versus host disease.For the central nervous system leukemia,intrathecal injection of rituximab is safe and effective.
- acute lymphoblastic leukemia /
- rituximab /
- CD20

HTML全文

参考文献(13)

[1]	GOEKBUGET N,HOELZER D.Novel antibody-based therapy for acute lymphoblastic leukemia[J].Best Pract Res Clin Haematol,2006,19:701-713.
[2]	JEHA S,BEHM F,PEI D,et al.Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia[J].Blood,2006,108:3302-3304.
[3]	聂述山,赵文理,季正华,等.CD20阳性儿童前B急性淋巴细胞白血病临床特点与预后分析[J].中华血液学杂志,2011,32(4):275-277.
[4]	THOMAS D A,O'BRIEN S,JORGENSEN J L,et al.Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphohlastic leukemia[J].Blood,2009,113:6330-6337.
[5]	MAURY S,HUGUET F,LEGUAY T,et al.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic Jeukemia[J].Haematologica,2010,95:324-328.
[6]	MANNELLI F,GIANFALDONI G,INTERMESOLI T,et al.CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia:new insights from the molecular study of minimal residual disease[J].Haematologica,2012,97:568-571.
[7]	GRIFFIN T C,WEITZMAN S,WEINSTEIN H,et al.A Study of rituximab and ifosfamide,carboplatin,and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20⁺) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia:a report from the Children's Oncology Group[J].Pediatr Blood Cancer,2009,52:177-181.
[8]	THOMAS D A,O'BRIEN S,FADERL S,et al.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia[J].J Clin Oncol,2010,28:3880-3889.
[9]	RIZZIERI D A,JOHNSON J L,BYRD J C,et al.Efficacy and toxicity of rituximab and brief duration,high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma:Cancer and Leukemia Group B (CALGB) Study10002[J].Blood,2010,116:858-861.
[10]	THOMAS D A,FADERL S,O'BRIEN S,et al.Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia[J].Cancer,2006,106:1569-1580.
[11]	KEBRIAEI P,SALIBA R M,MA C,et al.Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia[J].Bone Marrow Transplant,2006,38:203-209.
[12]	LUIS V,ROCIO C.Safety of intrathecal rituximab as prophylaxis or treatment in CD20⁺ acute lymphoblastic and aggressive lymphoma:report from a mexican pilot study[J].Blood,2006,108:4713-4715.
[13]	JAIME-PEREZ J C,RODRIGUEZ-ROMO L N,GONZALEZ-LLANO O,et al.Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy[J].Br J Haematol,2009,144:794-795.